220 related articles for article (PubMed ID: 34586888)
21. Plasma kinetics of mature PCSK9, furin-cleaved PCSK9, and Lp(a) with or without administration of PCSK9 inhibitors in acute myocardial infarction.
Nakamura A; Kanazawa M; Kagaya Y; Kondo M; Sato K; Endo H; Nozaki E
J Cardiol; 2020 Oct; 76(4):395-401. PubMed ID: 32439340
[TBL] [Abstract][Full Text] [Related]
22. Evolocumab prevents atrial fibrillation in rheumatoid arthritis rats through restraint of PCSK9 induced atrial remodeling.
Han X; Gao Y; He M; Luo Y; Wei Y; Duan Y; Zhang S; Yu H; Kan J; Hou T; Zhang Y; Li Y
J Adv Res; 2024 Jul; 61():211-221. PubMed ID: 37709197
[TBL] [Abstract][Full Text] [Related]
23. Impact of Target-Mediated Elimination on the Dose and Regimen of Evolocumab, a Human Monoclonal Antibody Against Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9).
Gibbs JP; Doshi S; Kuchimanchi M; Grover A; Emery MG; Dodds MG; Gibbs MA; Somaratne R; Wasserman SM; Blom D
J Clin Pharmacol; 2017 May; 57(5):616-626. PubMed ID: 27861991
[TBL] [Abstract][Full Text] [Related]
24. Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) Single Domain Antibodies Are Potent Inhibitors of Low Density Lipoprotein Receptor Degradation.
Weider E; Susan-Resiga D; Essalmani R; Hamelin J; Asselin MC; Nimesh S; Ashraf Y; Wycoff KL; Zhang J; Prat A; Seidah NG
J Biol Chem; 2016 Aug; 291(32):16659-71. PubMed ID: 27284008
[TBL] [Abstract][Full Text] [Related]
25. The cholesterol uptake regulator PCSK9 promotes and is a therapeutic target in APC/KRAS-mutant colorectal cancer.
Wong CC; Wu JL; Ji F; Kang W; Bian X; Chen H; Chan LS; Luk STY; Tong S; Xu J; Zhou Q; Liu D; Su H; Gou H; Cheung AH; To KF; Cai Z; Shay JW; Yu J
Nat Commun; 2022 Jul; 13(1):3971. PubMed ID: 35803966
[TBL] [Abstract][Full Text] [Related]
26. Circulating Rather Than Intestinal PCSK9 (Proprotein Convertase Subtilisin Kexin Type 9) Regulates Postprandial Lipemia in Mice.
Garçon D; Moreau F; Ayer A; Dijk W; Prieur X; Arnaud L; Roubtsova A; Seidah N; Prat A; Cariou B; Le May C
Arterioscler Thromb Vasc Biol; 2020 Sep; 40(9):2084-2094. PubMed ID: 32673528
[TBL] [Abstract][Full Text] [Related]
27. From lipoprotein apheresis to proprotein convertase subtilisin/kexin type 9 inhibitors: Impact on low-density lipoprotein cholesterol and C-reactive protein levels in cardiovascular disease patients.
Zenti MG; Altomari A; Lupo MG; Botta M; Bonora E; Corsini A; Ruscica M; Ferri N
Eur J Prev Cardiol; 2018 Nov; 25(17):1843-1851. PubMed ID: 30058841
[TBL] [Abstract][Full Text] [Related]
28. SPTBN1 suppresses the progression of epithelial ovarian cancer via SOCS3-mediated blockade of the JAK/STAT3 signaling pathway.
Chen M; Zeng J; Chen S; Li J; Wu H; Dong X; Lei Y; Zhi X; Yao L
Aging (Albany NY); 2020 Jun; 12(11):10896-10911. PubMed ID: 32516133
[TBL] [Abstract][Full Text] [Related]
29. MiR-203 regulates JAK-STAT pathway in affecting pancreatic cancer cells proliferation and apoptosis by targeting SOCS3.
Lin XM; Chen H; Zhan XL
Eur Rev Med Pharmacol Sci; 2019 Aug; 23(16):6906-6913. PubMed ID: 31486490
[TBL] [Abstract][Full Text] [Related]
30. Nrf2 induces lipocyte phenotype via a SOCS3-dependent negative feedback loop on JAK2/STAT3 signaling in hepatic stellate cells.
Lu C; Xu W; Shao J; Zhang F; Chen A; Zheng S
Int Immunopharmacol; 2017 Aug; 49():203-211. PubMed ID: 28601022
[TBL] [Abstract][Full Text] [Related]
31. Targeting PCSK9 Ameliorates Graft Vascular Disease in Mice by Inhibiting NLRP3 Inflammasome Activation in Vascular Smooth Muscle Cells.
Zou Y; Chen Z; Zhang X; Yu J; Xu H; Cui J; Li Y; Niu Y; Zhou C; Xia J; Wu J
Front Immunol; 2022; 13():894789. PubMed ID: 35720337
[TBL] [Abstract][Full Text] [Related]
32. Relationship Between Low-Density Lipoprotein Cholesterol and Lipoprotein(a) Lowering in Response to PCSK9 Inhibition With Evolocumab.
Shapiro MD; Minnier J; Tavori H; Kassahun H; Flower A; Somaratne R; Fazio S
J Am Heart Assoc; 2019 Feb; 8(4):e010932. PubMed ID: 30755061
[TBL] [Abstract][Full Text] [Related]
33. Efficacy of Shoushen granule on adenosine triphosphate binding cassette transporter A1, proprotein convertase subtilisin/kexin type 9 and toll-like receptor 4/nuclear factor kappa-B signaling pathway in ApoE-knockout mice.
Li S; Cao H; Shen D; Chen C; Xing S; Dou F; Jia Q
J Tradit Chin Med; 2019 Aug; 39(4):524-534. PubMed ID: 32186100
[TBL] [Abstract][Full Text] [Related]
34. Impact of proprotein convertase subtilisin/kexin type 9 inhibition with evolocumab on the postprandial responses of triglyceride-rich lipoproteins in type II diabetic subjects.
Taskinen MR; Björnson E; Andersson L; Kahri J; Porthan K; Matikainen N; Söderlund S; Pietiläinen K; Hakkarainen A; Lundbom N; Nilsson R; Ståhlman M; Adiels M; Parini P; Packard C; Borén J
J Clin Lipidol; 2020; 14(1):77-87. PubMed ID: 31917184
[TBL] [Abstract][Full Text] [Related]
35. Scoparone exerts anti-tumor activity against DU145 prostate cancer cells via inhibition of STAT3 activity.
Kim JK; Kim JY; Kim HJ; Park KG; Harris RA; Cho WJ; Lee JT; Lee IK
PLoS One; 2013; 8(11):e80391. PubMed ID: 24260381
[TBL] [Abstract][Full Text] [Related]
36. miRNA-221-3p derived from M2-polarized tumor-associated macrophage exosomes aggravates the growth and metastasis of osteosarcoma through SOCS3/JAK2/STAT3 axis.
Liu W; Long Q; Zhang W; Zeng D; Hu B; Liu S; Chen L
Aging (Albany NY); 2021 Aug; 13(15):19760-19775. PubMed ID: 34388111
[TBL] [Abstract][Full Text] [Related]
37. Inhibitory effects of suppressor of cytokine signaling 3 on inflammatory cytokine expression and migration and proliferation of IL-6/IFN-γ-induced vascular smooth muscle cells.
Xiang S; Dong NG; Liu JP; Wang Y; Shi JW; Wei ZJ; Hu XJ; Gong L
J Huazhong Univ Sci Technolog Med Sci; 2013 Oct; 33(5):615-622. PubMed ID: 24142708
[TBL] [Abstract][Full Text] [Related]
38. [Effects of exogenous suppressor of cytokine signaling on cell apoptosis in ectopic endometrial stromal cells].
Li M; Ruan F; Zhan H; Fei X; Ma J; Lin J
Zhonghua Yi Xue Za Zhi; 2014 Jan; 94(1):55-8. PubMed ID: 24721309
[TBL] [Abstract][Full Text] [Related]
39. In vivo and in vitro effects of microRNA-221 on hepatocellular carcinoma development and progression through the JAK-STAT3 signaling pathway by targeting SOCS3.
Huang S; Zhou D; Li YX; Ming ZY; Li KZ; Wu GB; Chen C; Zhao YN
J Cell Physiol; 2019 Apr; 234(4):3500-3514. PubMed ID: 30370582
[TBL] [Abstract][Full Text] [Related]
40. Protective effects of SOCS3 overexpression in high glucose‑induced lung epithelial cell injury through the JAK2/STAT3 pathway.
Duan WN; Xia ZY; Liu M; Sun Q; Lei SQ; Wu XJ; Meng QT; Leng Y
Mol Med Rep; 2017 Sep; 16(3):2668-2674. PubMed ID: 28713982
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
